Pure redox-sensitive paclitaxel–maleimide prodrug nanoparticles: Endogenous albumin-induced size switching and improved antitumor efficiency

Emerging well-tailored nanoparticulate delivery system based on in situ regulation of the protein corona

(2020) Zhenbao Li et al.   JOURNAL OF CONTROLLED RELEASE

Precisely albumin-hitchhiking tumor cell-activated reduction/oxidation-responsive docetaxel prodrugs for the hyperselective treatment of breast cancer

(2018) Wei Wei et al.   JOURNAL OF CONTROLLED RELEASE

In vivo tailor-made protein corona of a prodrug-based nanoassembly fabricated by redox dual-sensitive paclitaxel prodrug for the superselective treatment of breast cancer

(2018) Dong Zhang et al.   Biomaterials Science

Co-delivery of paclitaxel and cisplatin in poly(2-oxazoline) polymeric micelles: Implications for drug loading, release, pharmacokinetics and outcome of ovarian and breast cancer treatments

(2018) Xiaomeng Wan et al.   BIOMATERIALS

An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo

(2017) Josef Mayr et al.   Chemical Science

Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review

(2016) Manju Kanamala et al.   BIOMATERIALS

Tailoring nanoparticle designs to target cancer based on tumor pathophysiology

(2016) Edward A. Sykes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Facile Fabrication of Tumor Redox-Sensitive Nanoassemblies of Small-Molecule Oleate Prodrug as Potent Chemotherapeutic Nanomedicine

(2016) Cong Luo et al.   Small

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

(2015) Edgar Pérez-Herrero et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Albumin and its application in drug delivery

(2014) Darrell Sleep   Expert Opinion on Drug Delivery

Prodrug-based nanoparticulate drug delivery strategies for cancer therapy

(2014) Cong Luo et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Drug resistance in metastatic castration-resistant prostate cancer

(2010) Bostjan Seruga et al.   Nature Reviews Clinical Oncology